Isis, OncoGenex Technologies deal
The partners amended a 2001 deal under which Isis received rights to co-develop and market OncoGenex’s OGX-011. OncoGenex will now pay all development costs for the second-generation antisense inhibitor of clusterin mRNA. Originally, OncoGenex was responsible for 65% of the costs. Also, Isis is eligible for a portion of milestones OncoGenex receives from potential future license agreements for OGX-011, and for up to a 7% royalty regardless of future licensing. Isis was eligible for 35% of revenues from OGX-011 under the original deal. OGX-011 is in Phase II testing to treat castration-resistant prostate cancer (CRPC), breast cancer and non-small cell lung cancer (NSCLC). The partners’ co-development deals for OGX-427 and OGX-225 are unchanged. OGX-427 is a second-generation antisense inhibitor of Hsp27 that is in Phase I trials for cancer. OGX-225 is a second-generation antisense inhibitor of insulin-like growth factor binding protein 2 ( IGFBP2) that is in preclinical testing for solid tumors (see BioCentury, March 21 & May 2, 2005). ...